Getinge AB (OTCMKTS:GNGBY) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 800 shares, a growth of 166.7% from the September 15th total of 300 shares. Based on an average daily volume of 1,600 shares, the short-interest ratio is currently 0.5 days.
Several equities research analysts have commented on the stock. Berenberg Bank reaffirmed a “buy” rating on shares of Getinge in a research note on Wednesday, July 21st. AlphaValue raised shares of Getinge from a “reduce” rating to a “buy” rating and set a $41.32 target price for the company in a research note on Monday, July 26th. Zacks Investment Research downgraded shares of Getinge from a “buy” rating to a “hold” rating in a research report on Tuesday, August 24th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Getinge in a research report on Monday, July 19th. Finally, Pareto Securities downgraded shares of Getinge from a “buy” rating to a “hold” rating in a research report on Tuesday, June 29th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $44.16.
Shares of GNGBY stock remained flat at $$39.26 during trading hours on Thursday. 108 shares of the stock traded hands, compared to its average volume of 1,612. The stock has a market cap of $9.98 billion, a P/E ratio of 23.51 and a beta of 0.88. Getinge has a 52 week low of $19.37 and a 52 week high of $44.80. The company has a 50 day moving average of $41.76 and a 200 day moving average of $37.74. The company has a quick ratio of 1.93, a current ratio of 2.96 and a debt-to-equity ratio of 0.20.
Getinge AB is a medical technology company specializes in providing equipment, systems, operating rooms, intensive-care units to the healthcare and the life science industries. It engages in supplying of solutions for theaters, intensive care units, sterilization centers and companies and institutions within life science.
Recommended Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Getinge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Getinge and related companies with MarketBeat.com's FREE daily email newsletter.